Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST4WARD: Certolizumab Pegol Monotherapy in RA
NCT00548834Phase 3Completed
- Sponsor
- UCB
- Start
- Jun 2003
- Primary completion
- Jul 2004
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Started Jun 2003; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00548834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00548834.